Skip to main content
Part of Sickle Cell Disease on Somebody To Talk To

Sickle Cell Disease clinical trials near you

A clinical trial is a research study that tests whether a treatment is safe and works. Taking part is always your choice, and you can stop at any time. Listing a study here is not a recommendation — talk it through with your own team.

138 recruiting studiesFrom ClinicalTrials.gov (opens in a new tab)

Trial results

8 shown of 138

8 shown of 138 clinical trials.

  1. RecruitingPhase 2InterventionalNCT05736419

    A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

    Sickle Cell Disease, Thalassemia, Beta, Thalassemia

    Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs that lower the activity of the body's immune system (immune suppression), before standard conditioning therapy and HCT may help prevent serious side effects, including graft failure and GvHD. In this study, depending on how participants' body responds to the fludarabine and dexamethasone, the study doctor may decide participants should receive another drug, called cyclophosphamide, instead of fludarabine. In addition, depending on the results of participants' routine blood tests, participants may receive the drugs bortezomib and rituximab, which also help with immune suppression.

    Sites
    6
    Target
    24
    Study sites
    Basking Ridge, US +5 more

    Sponsor: Memorial Sloan Kettering Cancer Center

    View on ClinicalTrials.gov(opens in a new tab)
  2. RecruitingPhase 1InterventionalNCT04055818

    A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

    Sickle Cell Disease

    A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).

    Sites
    1
    Target
    20
    Study sites
    Chicago, US

    Sponsor: EpiDestiny, Inc.

    View on ClinicalTrials.gov(opens in a new tab)
  3. RecruitingPhase 1, Phase 2InterventionalNCT06481306

    A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

    Anemia, Sickle Cell, Healthy Volunteers

    The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

    Sites
    32
    Target
    224
    Study sites
    Birmingham, US +31 more

    Sponsor: Bristol-Myers Squibb

    View on ClinicalTrials.gov(opens in a new tab)
  4. RecruitingPhase 3InterventionalNCT06612268

    A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

    Sickle Cell Disease

    This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.

    Sites
    175
    Target
    510
    Study sites
    Birmingham, US +174 more

    Sponsor: Novo Nordisk A/S

    View on ClinicalTrials.gov(opens in a new tab)
  5. RecruitingPhase 2InterventionalNCT06198712

    A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

    Sickle Cell Disease

    The purpose of this study is to evaluate the pharmacokinetics and safety of etavopivat in paediatric participants with sickle cell disease (SCD). Participants will receive etavopivat and will be enrolled in a staggered manner, starting with the oldest age group and followed sequentially by younger cohorts after review of pharmacokinetic and safety data from the preceding cohort. All participants will undergo a 24-week primary treatment period followed by a 72-week extension treatment period to further evaluate long-term safety and pharmacokinetics of etavopivat. The total duration of the study will be approximately 96 weeks.

    Sites
    18
    Target
    95
    Study sites
    Toronto, CA +17 more

    Sponsor: Forma Therapeutics, Inc.

    View on ClinicalTrials.gov(opens in a new tab)
  6. RecruitingPhase 3InterventionalNCT07656415

    A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

    Sickle Cell Disease

    The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.

    Sites
    5
    Target
    159
    Study sites
    Indianapolis, US +4 more

    Sponsor: Agios Pharmaceuticals, Inc.

    View on ClinicalTrials.gov(opens in a new tab)
  7. RecruitingPhase 3InterventionalNCT06439082

    A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

    Sickle Cell Disease

    A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

    Sites
    36
    Target
    354
    Study sites
    Birmingham, US +35 more

    Sponsor: Novartis Pharmaceuticals

    View on ClinicalTrials.gov(opens in a new tab)
  8. RecruitingPhase 2InterventionalNCT04201210

    A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

    Sickle Cell Anemia, HbS Disease, Hemoglobin S Disease, Sickle Cell Disorders, Sickling Disorder Due to Hemoglobin S, Sickle Cell Disease

    HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory. With the lack of a suitable donor for the vast majority of patients, the major question of this trial is, if a haploidentical αß/CD19+ T-cell depleted HSCT can be a valid alternative to a MSD HSCT. The main challenge in non-malignant diseases is to offer a safe and GvHD-free HSCT without rejection.

    Sites
    9
    Target
    212
    Study sites
    Vienna, AT +8 more

    Sponsor: University of Regensburg

    View on ClinicalTrials.gov(opens in a new tab)